Survey and Research Archives | Be Korea-savvy

Archive by category Survey and Research

Four in Five Executive Agree Agility is Most Important Characteristic of a Successful Organization

Four in Five Executive Agree Agility is Most Important Characteristic of a Successful Organization

DENVER, Col., Sept. 18 (Korea Bizwire) – A new report by Forbes Insights finds 81 percent of respondents agree on the critical importance of agility when it comes to leading a successful organization. The report, “The Elusive Agile Enterprise,” was sponsored by Scrum Alliance, a Scrum certifying body and the largest professional association of Agile practitioners [...]

AI and Related Technologies Could Create Around 90 Million More Jobs in China than They Displace over Next Two Decades

AI and Related Technologies Could Create Around 90 Million More Jobs in China than They Displace over Next Two Decades

TIANJIN, China, Sept. 18 (Korea Bizwire) — AI and related technologies such as robots, drones and autonomous vehicles could provide a net boost to employment in China of around 12% over the next two decades, equating to around 90 million additional jobs. Launching the analysis at the World Economic Forum Annual Meeting of the New [...]

Inovio Develops Novel H3N2 Influenza DNA Vaccine That Generates Cross-Reactive Responses and Provides Complete Protection Against Lethal Preclinical Challenges

Inovio Develops Novel H3N2 Influenza DNA Vaccine That Generates Cross-Reactive Responses and Provides Complete Protection Against Lethal Preclinical Challenges

PLYMOUTH MEETING, Pa., Sept. 17 (Korea Bizwire) — Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that its SynCon® vaccine approach using a collection of DNA antigens generated broadly protective antibody responses against the most deadly strains of the H3N2 influenza viruses from the past 50 years and provided complete protection against heterologous lethal challenge in a [...]

Checkpoint Therapeutics Announces Encouraging Safety and Efficacy Data from Phase 1/2 Clinical Trial of EGFR Inhibitor CK-101

Checkpoint Therapeutics Announces Encouraging Safety and Efficacy Data from Phase 1/2 Clinical Trial of EGFR Inhibitor CK-101

NEW YORK, Sept. 6 (Korea Bizwire) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers, today announced positive preliminary safety and efficacy data from an ongoing Phase 1/2 clinical trial of CK-101 (also known as RX518), [...]

Inovio Doses 1st Subject in Phase 1/2 Clinical Trial for Vaccine Against Deadly MERS Infection

Inovio Doses 1st Subject in Phase 1/2 Clinical Trial for Vaccine Against Deadly MERS Infection

PLYMOUTH MEETING, Pa., Sept. 5 (Korea Bizwire) — Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today announced the dosing of the first subject with its vaccine to prevent infection from the deadly MERS virus (Middle East Respiratory Syndrome) in a Phase 1/2a study to evaluate INO-4700 (or GLS-5300). The trial is ongoing in South Korea sponsored [...]

Inovio and Korean Partner Dose 1st Subject in Trial to Develop World’s First Vaccine to Prevent Hepatitis C Infection

Inovio and Korean Partner Dose 1st Subject in Trial to Develop World’s First Vaccine to Prevent Hepatitis C Infection

PLYMOUTH MEETING, Pa., and SEOUL, Korea, Sept. 4 (Korea Bizwire) — Inovio Pharmaceuticals, Inc. (NASDAQ:INO) and GeneOne Life Science (KSE: 011000) today announced they have dosed the first patient in a Phase 1 study designed to evaluate a preventive vaccine against hepatitis C infection. Recruitment has already begun in South Korea, where GeneOne is responsible [...]

Global Survey Shows Companies Are Using More Automation in Cybersecurity, But Still Have Work to Do

Global Survey Shows Companies Are Using More Automation in Cybersecurity, But Still Have Work to Do

SAN JOSE, Calif., Aug. 28 (Korea Bizwire) — Skybox® Security, a global leader in cybersecurity management, has released the results of a global survey conducted by Osterman Research, Understanding Security Processes and the Need to Automate. The survey, which includes responses from 465 senior security leaders at large enterprises in the U.S., EMEA and APAC,* reveals [...]

PwC Study Shows Four Out of Five Executives Surveyed (84%) Report Blockchain Initiatives Underway

PwC Study Shows Four Out of Five Executives Surveyed (84%) Report Blockchain Initiatives Underway

LONDON, Aug. 28 (Korea Bizwire) — 84% of executives surveyed by PwC, report blockchain initiatives underway – 15% fully live. The new research from PwC – Blockchain is here. What’s your next move? – surveyed 600 executives in 15 countries and territories, on their development of blockchain and views on its potential. As blockchain rewires [...]

Checkpoint Therapeutics Announces Clinical Data on EGFR Inhibitor CK-101 Selected for Late-Breaking Oral Presentation at IASLC 19th World Conference on Lung Cancer

Checkpoint Therapeutics Announces Clinical Data on EGFR Inhibitor CK-101 Selected for Late-Breaking Oral Presentation at IASLC 19th World Conference on Lung Cancer

NEW YORK, Aug. 13 (Korea Bizwire) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers, today announced that preliminary safety and efficacy data from a Phase 1/2 clinical trial of CK-101 (also known as RX518), a [...]

Neuralstem Announces NSI-189 Granted Orphan Drug Designation from the U.S. FDA for the Treatment of Angelman Syndrome

Neuralstem Announces NSI-189 Granted Orphan Drug Designation from the U.S. FDA for the Treatment of Angelman Syndrome

GERMANTOWN, Md., Aug. 9 (Korea Bizwire) — Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell technology, today announced that the U.S. Food and Drug Administration has granted orphan drug designation to NSI-189 for the treatment of Angelman syndrome. “Angelman Syndrome is a rare disease [...]